<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070704</url>
  </required_header>
  <id_info>
    <org_study_id>NN9068-4331</org_study_id>
    <secondary_id>U1111-1185-0871</secondary_id>
    <nct_id>NCT03070704</nct_id>
  </id_info>
  <brief_title>Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India</brief_title>
  <official_title>A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this study is to evaluate long term safety and
      efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Request for the study waived by Indian Health Authorities
  </why_stopped>
  <start_date type="Anticipated">August 16, 2017</start_date>
  <completion_date type="Anticipated">August 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent Adverse Events (AEs)</measure>
    <time_frame>Year 0-1</time_frame>
    <description>Count and % of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>Year 0-1</time_frame>
    <description>Count and % of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Drug Reactions (SADRs)</measure>
    <time_frame>Year 0-1</time_frame>
    <description>Count and % of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Drug Reactions (ADRs)</measure>
    <time_frame>Year 0-1</time_frame>
    <description>Count and % of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of confirmed hypoglycaemic episodes</measure>
    <time_frame>Year 0-1</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the level of glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>Year 0, Year 1</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the level of Fasting Plasma/Blood Glucose (FPG/FBG) from baseline</measure>
    <time_frame>Year 0, Year 1</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving the target level of HbA1c below 7%</measure>
    <time_frame>Year 1</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Year 0, Year 1</time_frame>
    <description>Measured in kg and/or %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients withdrawn due to ineffective therapy</measure>
    <time_frame>Year 1</time_frame>
    <description>Count of withdrawals</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin degludec /liraglutide</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/liraglutide</intervention_name>
    <description>Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician</description>
    <arm_group_label>Insulin degludec /liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Based on the clinical judgement of their treating physician, patients with type 2 diabetes
        mellitus will be initiated on Xultophy™ according to routine clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any study-related activities. Study-related
             activities are any procedures that are related to the recording of data and
             determining the suitability for the study according to the protocol. Some specific
             historical data collected before informed consent is obtained can be used as baseline
             data (HbA1c, FPG/FBG and others)

          -  The decision to initiate treatment with commercially available Xultophy™ has been made
             by the patient/Legally Acceptable Representative (LAR) and the treating physician
             before and independently from the decision to include the patient in this study

          -  Male or female, age at least 18 years at the time of signing the informed consent

          -  Patients diagnosed with type 2 diabetes mellitus

          -  Patients who are scheduled to start treatment with Xultophy™ based on the clinical
             judgement of their treating physician

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to Xultophy™, any of the active substances, any of
             the excipients or any related products

          -  Previous participation in this study. Participation is defined as signed informed
             consent

          -  Mental incapacity, unwillingness or language barriers hindering adequate understanding
             or cooperation

          -  Females who are pregnant, breast-feeding or intend to become pregnant within the
             following 12 months

          -  Patients who are participating in other studies or clinical trials.

          -  Any disorder which in the opinion of the Physician might jeopardise subject's safety
             or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

